Curis Inc (CRIS) 2.03 $CRIS
Curis Reports First Quarter 2014 Financial Results
GlobeNewswire - Thu May 08, 6:08AM CDT
Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company developing novel drug candidates for the treatment of human cancers, today reported its financial results for the first quarter ended March 31, 2014.
Curis to Release First Quarter 2014 Financial Results and Hold Conference Call on May 8, 2014
GlobeNewswire - Thu May 01, 6:01AM CDT
Curis, Inc. (Nasdaq:CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, today announced that the Company will release its first quarter financial results on Thursday, May 8, 2014, before the market opens. The Company's management will also host a conference call on the same day at 9:00 A.M. Eastern Daylight Time to provide an overview of its proprietary clinical development programs, including CUDC-907 and CUDC-427, as well as its partnered programs, including Erivedge(R) (vismodegib) and Debio 0932. The Company's management will also provide a corporate update and review its financial results as of and for the first quarter ended March 31, 2014.
Curis Announces U.S. Patent Issuance Covering CUDC-907 Composition-of-Matter
GlobeNewswire - Wed Apr 30, 6:16AM CDT
Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today announced the issuance of U.S. Patent No. 8,710,219 entitled "Phosphoinositide 3-kinase inhibitor with a zinc binding moiety" that covers composition-of-matter for CUDC-907, Curis' dual histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) inhibitor. This patent, along with related patents issued in June 2013 (U.S. Patent no. 8,461,157) and February 2013 (U.S. Patent No. 8,367,663), covers a broad range of proprietary chemical entities that target HDAC and PI3K enzymes, and in some instances mammalian target of rapamycin (mTOR), within a single molecule for the treatment of certain human diseases. CUDC-907 is being investigated in a Phase 1 study in patients with relapsed/ refractory lymphoma or multiple myeloma.
Curis to Present at the Deutsche Bank 39th Annual Health Care Conference
GlobeNewswire - Wed Apr 30, 5:45AM CDT
Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers, today announced that the Company will present at the Deutsche Bank 39 Annual Health Care Conference at 4:50 p.m. ET on May 7, 2014, in Boston.
Biotech Stock Roundup: MannKind Soars on Panel Vote, Halozyme Plunges on Safety Concerns - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 09, 11:46AM CDT
Last week saw a couple of positive FDA panel votes as well as some disappointing data on experimental drugs.
Curis and Debiopharm Group Report Preclinical Data for Debio 0932 at AACR Annual Meeting 2014
PR Newswire - Tue Apr 08, 2:30AM CDT
Curis, Inc. (NASDAQ: CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology as well as companion diagnostics, today announced presentation of data for Debio 0932 at the Annual Meeting of the American Association for Cancer Research (AACR) that demonstrated synergy between Debio 0932 and various standard of care (SOC) agents in multiple in vitro and xenograft models of non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC). Debio 0932 is currently being investigated in a Phase 1/2 trial in combination with SOC agents in patients with advanced NSCLC and in Phase 1 trial in combination with everolimus, a mTOR inhibitor in advanced RCC patients.
Curis Reports CUDC-907 and CUDC-427 Data at AACR Annual Meeting 2014
GlobeNewswire - Mon Apr 07, 3:36PM CDT
CUDC-907 Modulates Expression of Certain Cytokines/ Chemokines, Potentially Targeting Tumor Microenvironment in Addition to Direct Effects on Cancer Cells
Curis and Debiopharm Group(TM) Report Preclinical Data for Debio 0932 at AACR Annual Meeting 2014
GlobeNewswire - Mon Apr 07, 3:02PM CDT
Curis, Inc. (Nasdaq:CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology as well as companion diagnostics, today announced the presentation of data for Debio 0932 at the Annual Meeting of the American Association for Cancer Research (AACR) that demonstrated synergy between Debio 0932 and various standard of care (SOC) agents in multiple in vitro and xenograft models of non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC). Debio 0932 is currently being investigated in a Phase 1/2 trial in combination with SOC agents in patients with advanced NSCLC and in a Phase 1 trial in combination with everolimus, a mTOR inhibitor, in advanced RCC patients.
Curis to Present at the 13th Annual Needham Healthcare Conference
GlobeNewswire - Wed Apr 02, 6:19AM CDT
Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers, today announced that the Company will present at the 13 Annual Needham Healthcare Conference at 1:40 p.m. ET on April 9, 2014, in New York City.
FDA Lifts Clinical Hold on Curis Cancer Drug, Shares Surge
Ben Fidler, The Motley Fool - Motley Fool - Mon Mar 31, 12:17PM CDT
Curis ' cancer drug just got a second lease on life. Now the Lexington, Mass.-based company will have to make something of it. Curis said today that the FDA has lifted the partial clinical hold on CUDC-427 , the experimental cancer drug it...
Global Protein Therapeutics Market 2012-2016: Patent-Expiration of Top-Selling Drugs Could Pose a Challenge to the Growth
M2 - Mon Mar 31, 11:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x5wp95/global_protein) has announced the addition of the "Global Protein Therapeutics Market 2012-2016" report to their offering. The analysts forecast the Global Protein Therapeutics market to grow at a CAGR of 7.08 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing prevalence of chronic diseases. The market has also been witnessing increasing outsourcing of drug development. The key vendors dominating this space include Roche Holding Ltd., Amgen Inc., Abbott Laboratories, J&J, and Novo Nordisk A/S. The other vendors mentioned in this report are AstraZeneca plc, Biogen Idec Inc., Eli Lilly and Co., Novartis International AG, Bristol Myers Squibb Co., Merck and Co. Inc., Pfizer Inc., Curis Inc., UCB S.A., Elan Corporations Plc, Human Genome Sciences Inc., Daiichi Sankyo Co. Ltd., and GlaxoSmithKline plc. Commenting on the report, an analyst from the Healthcare team said: The development and manufacture of drugs is a complex and time-consuming process, and also requires huge financial investments. As many vendors in the market are facing the problem of declining venture capital investments, they are increasingly following the strategy of outsourcing. Many vendors outsource different parts of the R&D process such as product characterization testing and toxicology testing to CROs. Likewise, a few vendors are increasingly outsourcing a part of their manufacturing process, or the entire manufacturing process to various organizations. Thus, the Global Protein Therapeutics market is currently witnessing the trend of increased outsourcing of drug development activities. For more information visit http://www.researchandmarkets.com/research/x5...al_protein About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Today’s Top Biotech Stories: Curis, Amgen, and Novartis
Leo Sun, The Motley Fool - Motley Fool - Mon Mar 31, 8:31AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at four biotech stocks -- Curis , Amgen ...
Curis Announces Removal of FDA Partial Clinical Hold on CUDC-427
GlobeNewswire - Mon Mar 31, 6:00AM CDT
Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today reported that the U.S. Food and Drug Administration (FDA) has notified the Company that its complete response submission to the November 2013 partial clinical hold on CUDC-427 has been reviewed and that the FDA has determined that it is safe to proceed under the IND. The FDA also indicated that detailed official correspondence regarding the determination will be released in the near future. Curis will provide additional details, if applicable, based upon further communications from the FDA as they become available.
Curis Announces Presentation of Data for CUDC-907, CUDC-427 and Debio 0932 at AACR Annual Meeting
GlobeNewswire - Mon Mar 31, 5:30AM CDT
Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today announced that Curis scientists and collaborators will present data from three programs at the Annual Meeting of American Association for Cancer Research (AACR) to be held from April 5 to 9 in San Diego, CA. Curis researchers will present data for two of its proprietary targeted cancer drug candidates, CUDC-907, a dual HDAC and PI3K inhibitor and CUDC-427, an antagonist of IAP proteins.
Stock to Watch: Curis Down 7.5% (CRIS)
Comtex SmarTrend(R) - Mon Mar 24, 10:43AM CDT
Curis (NASDAQ:CRIS) is one of today's worst performing low-priced stocks, down 7.5% to $2.86 on 1.1x average daily volume. Curis has traded 594,000 shares thus far today, vs. average volume of 535,000 shares per day. The stock has underperformed the Dow (-7.5% to the Dow's -0.3%) and underperformed the S&P 500 (-7.5% to the S&P's -0.7%) during today's trading.
Curis to Present at the 26th Annual ROTH Conference
GlobeNewswire - Tue Mar 04, 6:11AM CST
Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today announced that the Company will present at the 26 Annual ROTH Conference at 8:30 a.m. PT on March 11, 2014, in Laguna Niguel, CA.
Narrower-than-Expected Loss at Curis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 12:30PM CST
Curis reported fourth quarter 2013 net loss per share of 5 cents, narrower than the Zacks Consensus Estimate of a loss of 7 cents.
Curis to Present at the Cowen and Company 34th Annual Health Care Conference
GlobeNewswire - Tue Feb 25, 6:14AM CST
Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today announced that the Company will present at the Cowen and Company 34 Annual Health Care Conference at 4:50 p.m. ET on March 3, 2014, in Boston.
Small Business Owners Heading Into Retirement May Be Underestimating Value of Their Business: Scotiabank Study
Marketwire Canada - Tue Feb 25, 5:30AM CST
According to a recent Scotiabank poll, a quarter of Canada's small business owners (26%) expect their RRSP contributions to be their primary source of income in retirement, followed by proceeds from selling their business (17%), their savings (15%) and government pensions (8%).
Stock to Watch: Curis Up 5.4% (CRIS)
Comtex SmarTrend(R) - Thu Feb 20, 12:46PM CST
Curis (NASDAQ:CRIS) is one of today's best performing low-priced stocks, up 5.4% to $3.13 on 1.2x average daily volume. Thus far today, Curis has traded 564,000 shares, vs. average volume of 484,000 shares per day. The stock has outperformed the Dow (5.4% to the Dow's 0.7%) and outperformed the S&P 500 (5.4% to the S&P's 0.6%) during today's trading.
Curis Reports First Quarter 2014 Financial Results
GlobeNewswire - Thu May 08, 6:08AM CDT
Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company developing novel drug candidates for the treatment of human cancers, today reported its financial results for the first quarter ended March 31, 2014.
Curis to Release First Quarter 2014 Financial Results and Hold Conference Call on May 8, 2014
GlobeNewswire - Thu May 01, 6:01AM CDT
Curis, Inc. (Nasdaq:CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, today announced that the Company will release its first quarter financial results on Thursday, May 8, 2014, before the market opens. The Company's management will also host a conference call on the same day at 9:00 A.M. Eastern Daylight Time to provide an overview of its proprietary clinical development programs, including CUDC-907 and CUDC-427, as well as its partnered programs, including Erivedge(R) (vismodegib) and Debio 0932. The Company's management will also provide a corporate update and review its financial results as of and for the first quarter ended March 31, 2014.
Curis Announces U.S. Patent Issuance Covering CUDC-907 Composition-of-Matter
GlobeNewswire - Wed Apr 30, 6:16AM CDT
Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today announced the issuance of U.S. Patent No. 8,710,219 entitled "Phosphoinositide 3-kinase inhibitor with a zinc binding moiety" that covers composition-of-matter for CUDC-907, Curis' dual histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) inhibitor. This patent, along with related patents issued in June 2013 (U.S. Patent no. 8,461,157) and February 2013 (U.S. Patent No. 8,367,663), covers a broad range of proprietary chemical entities that target HDAC and PI3K enzymes, and in some instances mammalian target of rapamycin (mTOR), within a single molecule for the treatment of certain human diseases. CUDC-907 is being investigated in a Phase 1 study in patients with relapsed/ refractory lymphoma or multiple myeloma.
Curis to Present at the Deutsche Bank 39th Annual Health Care Conference
GlobeNewswire - Wed Apr 30, 5:45AM CDT
Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers, today announced that the Company will present at the Deutsche Bank 39 Annual Health Care Conference at 4:50 p.m. ET on May 7, 2014, in Boston.
Biotech Stock Roundup: MannKind Soars on Panel Vote, Halozyme Plunges on Safety Concerns - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 09, 11:46AM CDT
Last week saw a couple of positive FDA panel votes as well as some disappointing data on experimental drugs.
Curis and Debiopharm Group Report Preclinical Data for Debio 0932 at AACR Annual Meeting 2014
PR Newswire - Tue Apr 08, 2:30AM CDT
Curis, Inc. (NASDAQ: CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology as well as companion diagnostics, today announced presentation of data for Debio 0932 at the Annual Meeting of the American Association for Cancer Research (AACR) that demonstrated synergy between Debio 0932 and various standard of care (SOC) agents in multiple in vitro and xenograft models of non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC). Debio 0932 is currently being investigated in a Phase 1/2 trial in combination with SOC agents in patients with advanced NSCLC and in Phase 1 trial in combination with everolimus, a mTOR inhibitor in advanced RCC patients.
Curis Reports CUDC-907 and CUDC-427 Data at AACR Annual Meeting 2014
GlobeNewswire - Mon Apr 07, 3:36PM CDT
CUDC-907 Modulates Expression of Certain Cytokines/ Chemokines, Potentially Targeting Tumor Microenvironment in Addition to Direct Effects on Cancer Cells
Curis and Debiopharm Group(TM) Report Preclinical Data for Debio 0932 at AACR Annual Meeting 2014
GlobeNewswire - Mon Apr 07, 3:02PM CDT
Curis, Inc. (Nasdaq:CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology as well as companion diagnostics, today announced the presentation of data for Debio 0932 at the Annual Meeting of the American Association for Cancer Research (AACR) that demonstrated synergy between Debio 0932 and various standard of care (SOC) agents in multiple in vitro and xenograft models of non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC). Debio 0932 is currently being investigated in a Phase 1/2 trial in combination with SOC agents in patients with advanced NSCLC and in a Phase 1 trial in combination with everolimus, a mTOR inhibitor, in advanced RCC patients.
Curis to Present at the 13th Annual Needham Healthcare Conference
GlobeNewswire - Wed Apr 02, 6:19AM CDT
Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers, today announced that the Company will present at the 13 Annual Needham Healthcare Conference at 1:40 p.m. ET on April 9, 2014, in New York City.
FDA Lifts Clinical Hold on Curis Cancer Drug, Shares Surge
Ben Fidler, The Motley Fool - Motley Fool - Mon Mar 31, 12:17PM CDT
Curis ' cancer drug just got a second lease on life. Now the Lexington, Mass.-based company will have to make something of it. Curis said today that the FDA has lifted the partial clinical hold on CUDC-427 , the experimental cancer drug it...
Global Protein Therapeutics Market 2012-2016: Patent-Expiration of Top-Selling Drugs Could Pose a Challenge to the Growth
M2 - Mon Mar 31, 11:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x5wp95/global_protein) has announced the addition of the "Global Protein Therapeutics Market 2012-2016" report to their offering. The analysts forecast the Global Protein Therapeutics market to grow at a CAGR of 7.08 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing prevalence of chronic diseases. The market has also been witnessing increasing outsourcing of drug development. The key vendors dominating this space include Roche Holding Ltd., Amgen Inc., Abbott Laboratories, J&J, and Novo Nordisk A/S. The other vendors mentioned in this report are AstraZeneca plc, Biogen Idec Inc., Eli Lilly and Co., Novartis International AG, Bristol Myers Squibb Co., Merck and Co. Inc., Pfizer Inc., Curis Inc., UCB S.A., Elan Corporations Plc, Human Genome Sciences Inc., Daiichi Sankyo Co. Ltd., and GlaxoSmithKline plc. Commenting on the report, an analyst from the Healthcare team said: The development and manufacture of drugs is a complex and time-consuming process, and also requires huge financial investments. As many vendors in the market are facing the problem of declining venture capital investments, they are increasingly following the strategy of outsourcing. Many vendors outsource different parts of the R&D process such as product characterization testing and toxicology testing to CROs. Likewise, a few vendors are increasingly outsourcing a part of their manufacturing process, or the entire manufacturing process to various organizations. Thus, the Global Protein Therapeutics market is currently witnessing the trend of increased outsourcing of drug development activities. For more information visit http://www.researchandmarkets.com/research/x5...al_protein About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Today’s Top Biotech Stories: Curis, Amgen, and Novartis
Leo Sun, The Motley Fool - Motley Fool - Mon Mar 31, 8:31AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at four biotech stocks -- Curis , Amgen ...
Curis Announces Removal of FDA Partial Clinical Hold on CUDC-427
GlobeNewswire - Mon Mar 31, 6:00AM CDT
Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today reported that the U.S. Food and Drug Administration (FDA) has notified the Company that its complete response submission to the November 2013 partial clinical hold on CUDC-427 has been reviewed and that the FDA has determined that it is safe to proceed under the IND. The FDA also indicated that detailed official correspondence regarding the determination will be released in the near future. Curis will provide additional details, if applicable, based upon further communications from the FDA as they become available.
Curis Announces Presentation of Data for CUDC-907, CUDC-427 and Debio 0932 at AACR Annual Meeting
GlobeNewswire - Mon Mar 31, 5:30AM CDT
Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today announced that Curis scientists and collaborators will present data from three programs at the Annual Meeting of American Association for Cancer Research (AACR) to be held from April 5 to 9 in San Diego, CA. Curis researchers will present data for two of its proprietary targeted cancer drug candidates, CUDC-907, a dual HDAC and PI3K inhibitor and CUDC-427, an antagonist of IAP proteins.
Stock to Watch: Curis Down 7.5% (CRIS)
Comtex SmarTrend(R) - Mon Mar 24, 10:43AM CDT
Curis (NASDAQ:CRIS) is one of today's worst performing low-priced stocks, down 7.5% to $2.86 on 1.1x average daily volume. Curis has traded 594,000 shares thus far today, vs. average volume of 535,000 shares per day. The stock has underperformed the Dow (-7.5% to the Dow's -0.3%) and underperformed the S&P 500 (-7.5% to the S&P's -0.7%) during today's trading.
Curis to Present at the 26th Annual ROTH Conference
GlobeNewswire - Tue Mar 04, 6:11AM CST
Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today announced that the Company will present at the 26 Annual ROTH Conference at 8:30 a.m. PT on March 11, 2014, in Laguna Niguel, CA.
Narrower-than-Expected Loss at Curis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 12:30PM CST
Curis reported fourth quarter 2013 net loss per share of 5 cents, narrower than the Zacks Consensus Estimate of a loss of 7 cents.
Curis to Present at the Cowen and Company 34th Annual Health Care Conference
GlobeNewswire - Tue Feb 25, 6:14AM CST
Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today announced that the Company will present at the Cowen and Company 34 Annual Health Care Conference at 4:50 p.m. ET on March 3, 2014, in Boston.
Small Business Owners Heading Into Retirement May Be Underestimating Value of Their Business: Scotiabank Study
Marketwire Canada - Tue Feb 25, 5:30AM CST
According to a recent Scotiabank poll, a quarter of Canada's small business owners (26%) expect their RRSP contributions to be their primary source of income in retirement, followed by proceeds from selling their business (17%), their savings (15%) and government pensions (8%).
Stock to Watch: Curis Up 5.4% (CRIS)
Comtex SmarTrend(R) - Thu Feb 20, 12:46PM CST
Curis (NASDAQ:CRIS) is one of today's best performing low-priced stocks, up 5.4% to $3.13 on 1.2x average daily volume. Thus far today, Curis has traded 564,000 shares, vs. average volume of 484,000 shares per day. The stock has outperformed the Dow (5.4% to the Dow's 0.7%) and outperformed the S&P 500 (5.4% to the S&P's 0.6%) during today's trading.
